Cardiovascular Drugs and Therapy : Impact Factor & More
eISSN: 1573-7241pISSN: 0920-3206
Share this on:
Key Metrics
CiteScore 
5.6
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q1Pharmacology
SNIP
0.93
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Cardiovascular Drugs and Therapy
Cardiovascular Drugs and Therapy Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1987 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Cardiovascular Drugs and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Cardiovascular Drugs and Therapy
Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.
- 1 Jul 2026
- Cardiovascular drugs and therapy
Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).
- 1 Jul 2026
- Cardiovascular drugs and therapy
Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.
- 20 Jun 2026
- Cardiovascular drugs and therapy
Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.
- 19 Jun 2026
- Cardiovascular drugs and therapy
Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p.
- 18 Jun 2026
- Cardiovascular drugs and therapy
Beyond Branch Patency: Timing, Bleeding Phenotype, and Organ Risk in Antithrombotic Therapy After Branched EVAR.
- 10 Jun 2026
- Cardiovascular drugs and therapy
Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.
- 1 Jul 2026
- Cardiovascular drugs and therapy
Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).
- 1 Jul 2026
- Cardiovascular drugs and therapy
Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.
- 20 Jun 2026
- Cardiovascular drugs and therapy
Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.
- 19 Jun 2026
- Cardiovascular drugs and therapy
Shenfu Injection Inhibits Cardiac Fibroblast Activation and Improves Myocardial Fibrosis by Down-regulating M1 Macrophage-Derived Exosomal miR-155-5p.
- 18 Jun 2026
- Cardiovascular drugs and therapy
Beyond Branch Patency: Timing, Bleeding Phenotype, and Organ Risk in Antithrombotic Therapy After Branched EVAR.
- 10 Jun 2026
- Cardiovascular drugs and therapy
FAQs on Cardiovascular Drugs and Therapy
How long has Cardiovascular Drugs and Therapy been actively publishing? 
What is the publishing frequency of Cardiovascular Drugs and Therapy?
How many articles did Cardiovascular Drugs and Therapy publish last year?
What is the eISSN & pISSN for Cardiovascular Drugs and Therapy?
What is Citescore for Cardiovascular Drugs and Therapy?
What is SNIP score for Cardiovascular Drugs and Therapy?
What is the SJR for Cardiovascular Drugs and Therapy?
Who is the publisher of Cardiovascular Drugs and Therapy?
